Skip to main content

Lilly Announces $35 Monthly Cap on Insulin in Response to COVID-19

By Karena Yan

With unemployment rising, Lilly’s Insulin Value Program limits insulin prescription costs to $35 a month for people who are uninsured or who have commercial insurance

In response to the COVID-19 crisis, Lilly announced its new Insulin Value Program, which allows anyone who has commercial insurance or no insurance to fill his or her monthly prescription of Lilly insulin for $35. This program covers most Lilly insulins, including Humalog. The $35 cap applies regardless of number of insulin doses required.

Effective immediately, consumers can access this program by calling Lilly’s Diabetes Solution Center at 833-808-1234. The Solution Center is open 8 am to 8 pm (EDT) Monday through Friday. Representatives will help you get a co-pay card, either through email or US mail, which can be used at the pharmacy. People who already have a Lilly co-pay card do not need to take any action – active cards have automatically been reset to a $35 co-pay. 

Lilly representatives at the Solution Center can also help you find other options. This is helpful for people who are ineligible for the Insulin Value Program, including those who are on government insurance (Medicaid, Medicare, etc.). Some of the alternative cost-saving options are:

  • Free insulin for people with low income, or no income at all, that has been donated by Lilly to non-profit organizations. People with an urgent need for insulin and nowhere else to turn can contact the Solution Center for an immediate supply.

  • Half-priced generic version of Humalog (Insulin Lispro).

  • A separate co-pay card for Humulin R U-500 (insulin human injection, 500 units/mL) that allows for a monthly prescription fill for as little as $25 for people with commercial insurance.

  • A separate co-pay card for Baqsimi (glucagon) nasal powder that allows people with commercial insurance to pay as little as $25 for up to two devices.

While the Insulin Value Program was created in response to COVID-19,  Lilly notes that, as of now, there are “no plans” to end the program once the crisis eases.

The three insulin manufacturers – Lilly, Sanofi, and Novo Nordisk – have patient assistance programs for people who are uninsured and meet income eligibility requirements:

Sanofi and Novo Nordisk also have their own insulin savings programs. Each caps a monthly supply of their insulin at $99, though their eligibility criteria vary:

For a full list of insulin access programs, please see our Paying for Insulin resource page.

For more information on insulin during COVID-19, see our article on Getting Insulin During COVID-19

Share this article